Search

Fenoxaprop-ethyl

Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.

Albinterferon Alfa-2B

In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

Mavorixafor

Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficienc...

NM-702

M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase.

Naluzotan

1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline

1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline is a solid. This compound belongs to the isoquinolines and derivatives.

Epitestosterone

Epitestosterone is the 17-alpha isomer of testosterone, derived from pregnenolone via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol.

Sonlicromanol

Sonlicromanol is under investigation in clinical trial NCT04165239 (The KHENERGYZE Study).

Viagenpumatucel-L

Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

Efineptakin alfa

Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. … Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability.